# Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

> **NCT01158534** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** celecoxib
- **BIOLOGICAL:** recombinant interferon alfa-2b
- **OTHER:** polymerase chain reaction
- **OTHER:** laboratory biomarker analysis
- **OTHER:** reverse transcriptase-polymerase chain reaction
- **OTHER:** immunologic technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** flow cytometry

## Key facts

- **NCT ID:** NCT01158534
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158534, "Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01158534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*